HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 727-736

  Wang, Chunhong ^a   Fei, Guangru ^b   Liu, Zhongmin ^b   Li, Qinchuan ^b   Xu, Zengguang ^b   Ren, Tao ^b  

^a Qingdao Chest Hospital   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CpG oligonucleotide; HMGB1; Lung cancer; RAGE; TLR4; TLR9

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CPG OLIGODEOXYNUCLEOTIDE; CYCLIN DEPENDENT KINASE 2; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY; UPREGULATION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; GENE KNOCKDOWN TECHNIQUES; HMGB1 PROTEIN; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYRIBONUCLEOTIDES; PYRUVATES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; UP-REGULATION;

EID: 84863444409     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20555     Document Type: Article

References (36)

1. Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990; 1049:231-43; PMID:2200521.
2. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002; 72:1084-91; PMID:12488489.
3. Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009; 103:1949-53; PMID:19535236; http://dx.doi.org/10.1016/ j.rmed.2009.05.019.
4. Furuita K, Murata S, Jee JG, Ichikawa S, Matsuda A, Kojima C. Structural feature of bent DNA recognized by HMGB1. J Am Chem Soc 2011; 133:5788-90; PMID:21443191; http://dx.doi.org/10.1021/ja2013399.
5. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001; 7:315-21; PMID:11717586; http://dx.doi.org/10. 1177/09680519010070041401.
6. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13:2836-48; PMID:17504981; http://dx.doi.org/10.1158/1078-0432.CCR-06-1953.
7. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, et al. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010; 43:530-8; PMID:19933377; http://dx.doi.org/10.1165/rcmb. 2009-0269OC.
8. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17:189-201; PMID:16513409; http://dx.doi.org/10.1016/j.cytogfr.2006.01.003.
9. Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res 2011; 343:189-99; PMID:20835834; http://dx.doi.org/10.1007/s00441-010-1033-1.
10. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28:367-88; PMID:20192808; http://dx.doi.org/10.1146/annurev.immunol.021908.132603.
11. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, et al. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008; 99:1806-12; PMID:18616526.
12. Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003; 17:1295-7; PMID:12759333.
13. Tang D, Kang R, Zeh HJ, 3rd, Lotze MT. Highmobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799:131-40; PMID:20123075.
14. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 2007; 6:1704-9; PMID:17986857; http://dx.doi.org/10.4161/cbt.6.11.4826.
15. Xu L, Zhou Y, Liu Q, Luo JM, Qing M, Tang XY, et al. CXCR4/SDF-1 pathway is crucial for TLR9 agonist enhanced metastasis of human lung cancer cell. Biochem Biophys Res Commun 2009; 382:571-6; PMID:19302975; http://dx.doi.org/10. 1016/j.bbrc.2009.03.072.
16. Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, et al. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 2009; 15:623-30; PMID:19319670; http://dx.doi.org/10.1007/s12253-009-9162-0.
17. Xu L, Wang C, Wen Z, Yao X, Liu Z, Li Q, et al. Selective upregulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell. Immunol Lett 2010; 127:93-9; PMID:19854217; http://dx.doi.org/10. 1016/j.imlet.2009.10.002.
18. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110:1970-81; PMID:17548579; http://dx.doi.org/10.1182/blood-2006-09- 044776.
19. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61:1-9; PMID:15644117; http://dx.doi.org/10.1111/j.0300-9475.2005.01534.x.
20. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:917-24; PMID:16267105; http://dx.doi.org/10.1152/ajpcell.00401.2005.
21. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8:487-96; PMID:17417641; http://dx.doi.org/10.1038/ni1457.
22. Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, Motoyama A, et al. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 2011; 6:23132; PMID:21829704; http://dx.doi.org/10.1371/journal.pone.0023132.
23. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011; 117:3889-99; PMID:21858799; http://dx.doi.org/10.1002/cncr.25935.
24. Murad YM, Clay TM. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 2009; 23:361-75; PMID:19894778; http://dx.doi.org/10.2165/11316930.
25. Shen X, Hong L, Sun H, Shi M, Song Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 2009; 22:535-9; PMID:19639200.
26. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405:354-60; PMID:10830965; http://dx.doi.org/10.1038/35012626.
27. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7:777-89; PMID:18331236; http://dx.doi.org/10.2174/ 156652407783220697.
28. Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett 2011; 313:91-8; PMID:21945853; http://dx.doi.org/10.1016/j. canlet.2011.08.028.
29. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGFβ-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011; 30:2475-84; PMID:21278795; http://dx.doi.org/10.1038/onc.2010.619.
30. Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother 2011; 60:1211-20; PMID:21789594; http://dx.doi.org/10. 1007/s00262-011-1057-8.
31. Zhang YB, He FL, Fang M, Hua TF, Hu BD, Zhang ZH, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 2009; 36:1475-81; PMID:18763053; http://dx.doi.org/10.1007/s11033-008-9338-9.
32. Xu Z, Ren T, Xiao C, Li H, Wu T. Nickel promotes the invasive potential of human lung cancer cells via TLR4/MyD88 signaling. Toxicology 2011; 285:25-30; PMID:21473897; http://dx.doi.org/10.1016/j.tox.2011.03.016.
33. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44:2850-9; PMID:17328955; http://dx.doi.org/10.1016/j.molimm.2007.01.022.
34. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216:167-75; PMID:18680137; http://dx.doi.org/10.1002/path.2391.
35. -/- mice. J Clin Invest 2008; 118:183-94; PMID:18079965; http://dx.doi.org/10.1172/JCI32703.
36. Chen XM, O'Hara SP, Nelson JB, Splinter PL, Small AJ, Tietz PS, et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NFkappaB. J Immunol 2005; 175:7447-56; PMID:16301652.